Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design

Conditions: Erythema Interventions: Drug: MOB015B; Drug: 0.2% SLS; Drug: 0.9% Saline; Drug: MOB015B vehicle Sponsors: Moberg Pharma AB Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials